Journal Article Review Epublish
PubMed: 42614656 DOI: 10.3389/fgstr.2026.1860608
Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms.
Front Gastroenterol (Lausanne) 5:1860608
Authors: Faris Chater, Thomas D Butler, Jimmy K Limdi
Affiliations
- Department of Gastroenterology, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.
- Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
- University of Manchester, Manchester, United Kingdom.
Abstract
Inflammatory bowel diseases, encompassing Crohn's disease and ulcerative colitis, are chronic inflammatory disorders of the gastrointestinal tract. The recent expansion in advanced therapy options has not dramatically altered the ceiling of treatment efficacy. Therapeutic drug monitoring (TDM) of the serum drug levels and anti-drug antibodies has the potential to optimise treatment efficacy through dose adjustment. TDM has shown benefit with purine analogues and anti-tumour necrosis factor (TNF) therapy. Less is known about the role of TDM in non-anti-TNF advanced therapies. This review summarises the current evidence base for TDM in non-anti-TNF advanced therapies.
MeSH
Treatment Outcome, Pharmaceutical Preparations, Drug Monitoring, Drug Elimination Routes, Inflammatory Bowel Diseases, Therapeutics